Modalis Therapeutics Corporation

4883

JP3922600006

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 31/05/2024 BST			5-day change	1st Jan Change
69 ^JPY	-1.43%		-.--%	-44.35%

05-07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
04-30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

EdiGENE Corporation has Changed its Name to Modalis Therapeutics Corporation

August 29, 2019 at 03:32 am

EdiGENE Corporation changed its name to Modalis Therapeutics Corporation.

Latest news about Modalis Therapeutics Corporation

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	05-07	CI
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	04-30	CI
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	04-15	MT
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	02-23	MT
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	12-13	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	12-13	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	12-12	CI
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	11-29	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	11-06	CI
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	27/09/23	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	10/09/23	CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	07/08/23	CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	26/06/23	CI
Modalis Therapeutics to Grant Stock Options	16/06/23	MT
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting	19/04/23	CI
Modalis to Allot Stock Options	29/03/23	MT
Modalis Therapeutics to Overcome 2.6 Billion Yen Deficit in Retained Earnings	23/02/23	MT
Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collaboration on 205	12/01/23	CI
Modalis Therapeutics Corporation(TSE:4883) dropped from S&P Global BMI Index	19/09/22	CI
Modalis Therapeutics Issues Share Acquisition Rights	06/07/22	MT
Modalis Therapeutics to Issue Share Acquisition Rights	16/06/22	MT
Modalis Therapeutics Swings to Loss in Q1 on Growing Research Costs	10/05/22	MT
Modalis Therapeutics Adds Cardiomyopathy Therapy to In-House Pipeline	10/05/22	MT
Modalis Therapeutics Corporation Announces Addition of MDL-105 to In-house Pipelines	09/05/22	CI

Chart Modalis Therapeutics Corporation

Duration

Period

More charts

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-44.35%	16.44M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs

Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

EdiGENE Corporation has Changed its Name to Modalis Therapeutics Corporation

Latest news about Modalis Therapeutics Corporation

Chart Modalis Therapeutics Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs